NEW YORK (GenomeWeb News) – Genomas has won a $1.4 million grant from the National Institutes of Health to develop pharmacogenomic technology that will help doctors predict drug efficacy and side-effect risk for neuropsychiatric disease patients.

The company plans to use the Small Business Innovation Research grant to continue developing its PhyzioType Systems, which use genetic polymorphisms found through array genotyping and an algorithm to help doctors develop personalized drug prescriptions for antidepressants and antipsychotics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.